AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.47 USD | -4.50% |
|
-13.50% | -30.73% |
| May. 07 | Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading | MT |
| May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 210M | Sales 2025 * | 183M | Capitalization | 252M |
|---|---|---|---|---|---|
| Net income 2024 * | -182M | Net income 2025 * | -225M | EV / Sales 2024 * | 1.2 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.37 x |
| P/E ratio 2024 * |
-1.24
x | P/E ratio 2025 * |
-1.32
x | Employees | 389 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Agenus Inc.
More recommendations
More press releases
| 1 day | -4.50% | ||
| 1 week | -5.36% | ||
| Current month | -5.36% | ||
| 1 month | +13.86% | ||
| 3 months | -15.65% | ||
| 6 months | -30.08% | ||
| Current year | -30.73% |
1 week
10.70
14.04
1 month
4.7814.24
Current year
4.7818.98
1 year
4.7842.60
3 years
4.78135.80
5 years
4.78135.80
10 years
4.78203.20
| Managers | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 0 M€ | -3.26% | - | |
| 0.01% | 0 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 11.47 | -4.50% | 716,164 |
| 24-05-07 | 12.01 | -7.26% | 1,268,606 |
| 24-05-06 | 12.95 | -0.92% | 417,963 |
| 24-05-03 | 13.07 | +4.39% | 648,418 |
| 24-05-02 | 12.52 | -5.58% | 979,018 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.01
USD
Average target price
44.25
USD
Spread / Average Target
+268.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.73% | 252M | |
| +22.56% | 46.4B | |
| -1.51% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +10.13% | 26.01B | |
| -20.44% | 19.52B | |
| +26.45% | 12.43B | |
| -0.14% | 12.18B | |
| -0.47% | 12.13B |
- Stock Market
- Equities
- AGEN Stock